Pivotal clinical trials such as Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) [31] have shown that targeting inflammation through IL-1β inhibition reduces the risk of myocardial infarction and stroke independently of lipid levels [32]. Here, IL1B is linked to myocardial infarction.